---
title: "BMRN.US (BMRN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/BMRN.US/news.md"
symbol: "BMRN.US"
name: "BMRN.US"
parent: "https://longbridge.com/en/quote/BMRN.US.md"
datetime: "2026-05-20T22:23:39.310Z"
locales:
  - [en](https://longbridge.com/en/quote/BMRN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/BMRN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/BMRN.US/news.md)
---

# BMRN.US (BMRN.US) — Related News

### [BioMarin plans FDA filing in Q3 2026 for Voxzogo in hypochondroplasia](https://longbridge.com/en/news/287113812.md)
*2026-05-20T20:20:25.000Z*
> BioMarin plans to file a supplemental NDA with the FDA in Q3 2026 to expand VOXZOGO’s label to children with hypochondro

### [BioMarin drug acquired in buyout misses goal in rare disease study](https://longbridge.com/en/news/287075291.md)
*2026-05-20T13:30:31.000Z*
> BioMarin Pharmaceutical's experimental drug BMN 401, acquired through a buyout, failed to meet one of its two main objec

### [BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia | BMRN Stock News](https://longbridge.com/en/news/287114244.md)
*2026-05-20T12:20:00.000Z*
> BioMarin announced positive Phase 3 study results for VOXZOGO® (vosoritide) in children with hypochondroplasia, showing 

### [BioMarin’s ENERGY 3 trial of BMN 401 meets one co-primary endpoint](https://longbridge.com/en/news/287037760.md)
*2026-05-20T09:20:18.000Z*
> BioMarin Pharmaceutical's Phase III ENERGY 3 trial of BMN 401 for children with ENPP1 deficiency met one co-primary endp

### [Citigroup is optimistic about the catalysts and growth prospects, covering Ionis, Alnylam, and BioMarin with a buy rating](https://longbridge.com/en/news/286956616.md)
*2026-05-19T19:15:30.000Z*
> Citigroup has initiated coverage on the small and mid-cap biotech sector, giving "Buy" ratings to Ionis, Alnylam, and Bi